Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates

1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxone‑based therapy with mainly mild GI adverse events.​

2. Stewardship groups recommend using Nuzolvence as an additional option rather than replacing injectables, particularly for patients at high risk of loss to follow‑up or in whom parenteral therapy is impractical.

The Food and Drug Administration has recently authorized Nuzolvence (zoliflodacin) as the first oral, first‑in‑class option for uncomplicated urogenital gonorrhea, broadening choices beyond injectable ceftriaxone‑based regimens as detailed in its press release on two new oral gonorrhea therapies. Although the approval was granted on December 12, 2025, many clinicians are only beginning in early 2026 to incorporate this agent into sexually transmitted infection care pathways and urgent‑care order sets. In the pivotal phase 3 study, Nuzolvence demonstrated non‑inferior microbiologic cure rates versus standard ceftriaxone‑based therapy, with adverse events largely limited to mild gastrointestinal symptoms and the convenience of a single oral dose that fits readily into high‑throughput clinic workflows. Mechanistically, the drug inhibits bacterial DNA gyrase through a novel target, and infectious‑disease specialists have underscored that this mechanism may preserve activity against strains with expanding resistance to current cephalosporin‑based regimens, as summarized in antimicrobial‑stewardship coverage. Stewardship groups are therefore positioning Nuzolvence as an adjunctive option rather than a default replacement, recommending its use primarily for patients in whom parenteral therapy is challenging or not feasible. In the emergency department and in sexual health clinics, the single‑dose oral formulation may prove particularly valuable for individuals with unstable housing, competing priorities, or unreliable follow‑up. Public‑health officials are emphasizing that deployment of this regimen should be coupled with expanded diagnostic testing, robust partner services, and local resistance tracking to avoid repeating the rapid erosion of effectiveness seen with previous gonorrhea therapies. For patients, an effective oral, single‑visit regimen has the potential to reduce barriers related to injections, return visits, and stigma, thereby improving timely treatment of both symptomatic and incidentally detected infections. Clinicians managing high‑prevalence populations will need to consider how best to integrate Nuzolvence with existing dual‑therapy strategies, test‑of‑cure practices, and recommendations for rescreening. As 2026 advances, updated guidance from professional societies is anticipated to clarify how Nuzolvence should be prioritized relative to traditional injectable regimens, especially in jurisdictions with high background resistance or limited access to specialized sexually transmitted disease services. Primary care and urgent‑care teams may benefit from brief educational updates or clinical decision‑support prompts to ensure appropriate patient selection and dosing. Health‑system leaders will also be watching how pricing, coverage decisions, and supply stability affect real‑world uptake of this new oral gonorrhea therapy.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.